Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625875 | 0.83 | RAB9A (0.36) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL623360 | 0.81 | L3MBTL1 (0.50) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL624567 | 0.79 | NPC1 (0.54) | ABL1MDM2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24344114 | 0.75 | MDM2 (0.64) | ABL1MDM2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17673492 | 0.74 | L3MBTL1 (0.46) | ABL1NPC1RAB9A | |
| SCHEMBL27037591 | 0.73 | MAP4K1 (0.54) | ABL1MDM2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27038569 | 0.72 | MDM2 (0.49) | ABL1MDM2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30698945 | 0.72 | MDM2 (0.49) | ABL1MDM2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL954613 | 0.72 | ACVRL1 (0.57) | — | |
| SCHEMBL14060629 | 0.71 | MDM2 (0.51) | ABL1MDM2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2603216-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012021615-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, PIK3C2B, PIK3R1 | ABL1 652/4885MDM2 700/4885NPC1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.